B Cells and Autoantibodies in Multiple Sclerosis
AbstractWhile over the past decades T cells have been considered key players in the pathogenesis of multiple sclerosis (MS), it has only recently become evident that B cells have a major contributing role. Our understanding of the role of B cells has evolved substantially following the clinical success of B cell-targeting therapies and increasing experimental evidence for significant B cell involvement. Rather than mere antibody-producing cells, it is becoming clear that they are team players with the capacity to prime and regulate T cells, and function both as pro- and anti-inflammatory mediators. However, despite tremendous efforts, the target antigen(s) of B cells in MS have yet to be identified. The first part of this review summarizes the clinical evidence and results from animal studies pointing to the relevance of B cells in the pathogenesis of MS. The second part gives an overview of the currently known potential autoantigen targets. The third part recapitulates and critically appraises the currently available B cell-directed therapies. View Full-Text
Share & Cite This Article
Pröbstel, A.-K.; Sanderson, N.S.R.; Derfuss, T. B Cells and Autoantibodies in Multiple Sclerosis. Int. J. Mol. Sci. 2015, 16, 16576-16592.
Pröbstel A-K, Sanderson NSR, Derfuss T. B Cells and Autoantibodies in Multiple Sclerosis. International Journal of Molecular Sciences. 2015; 16(7):16576-16592.Chicago/Turabian Style
Pröbstel, Anne-Katrin; Sanderson, Nicholas S.R.; Derfuss, Tobias. 2015. "B Cells and Autoantibodies in Multiple Sclerosis." Int. J. Mol. Sci. 16, no. 7: 16576-16592.